# DFP-14323

Source: https://onco.cc/drugs/dfp-14323/  
OnCo record `dfp-14323` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DFP-14323 is an experimental small molecule from Delta-Fly Pharma, at a stage the company does not state for lung cancer; its current status is not stated.

## Summary

DFP-14323 is a small molecule (oral; low-dose ubenimex, also called bestatin) from Delta-Fly Pharma, with Nippon Chemiphar as licensee. Low-dose ubenimex (bestatin), a protease inhibitor, which the company says has stronger anti-tumour effect and improves immune function; presented with an EGFR inhibitor in lung cancer. The company does not state its stage; it is aimed at lung cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Stage not stated in the page text (the status chart is an image). No ClinicalTrials.gov record found; Japanese registries (jRCT) were not searched. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: DFP-14323
- Modality: Small molecule (oral; low-dose ubenimex, also called bestatin)
- Mechanism: Low-dose ubenimex (bestatin), a protease inhibitor, which the company says has stronger anti-tumour effect and improves immune function; presented with an EGFR inhibitor in lung cancer.

## Sources

- Delta-Fly Pharma: delta-flypharma.co.jp: https://www.delta-flypharma.co.jp/en/r-and-d
- Delta-Fly Pharma: delta-flypharma.co.jp: https://www.delta-flypharma.co.jp/en/r-and-d

## Connected records

- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)

---
JSON: https://onco.cc/api/v1/entities/dfp-14323.json